Treatment Persistence and Clinical Outcomes of Tumor Necrosis Factor Inhibitor Cycling or Switching to a New Mechanism of Action Therapy: ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2017-07-03

AUTHORS

Wenhui Wei, Keith Knapp, Li Wang, Chieh-I Chen, Gary L. Craig, Karen Ferguson, Sergio Schwartzman

ABSTRACT

IntroductionTo examine treatment persistence and clinical outcomes associated with switching from a tumor necrosis factor inhibitor (TNFi) to a medication with a new mechanism of action (MOA) (abatacept, anakinra, rituximab, tocilizumab, or tofacitinib) versus cycling to another TNFi (adalimumab, certolizumab pegol, etanercept, golimumab, or infliximab) among patients with rheumatoid arthritis.MethodsThis retrospective, longitudinal study included patients with rheumatoid arthritis in the JointMan® US clinical database who received a TNFi in April 2010 or later and either cycled to a TNFi or switched to a new MOA therapy by March 2015. Cox proportional hazards models were used for time to non-persistence (switching or discontinuing). An ordinary least squares regression model compared 1-year reduction from baseline for the Clinical Disease Activity Index (CDAI).ResultsThere were 332 (54.2%) TNFi cyclers and 281 (45.8%) new MOA switchers. During a median follow-up of 29.9 months, treatment persistence was 36.7% overall. Compared with new MOA switchers, TNFi cyclers were 51% more likely to be non-persistent (adjusted hazard ratio, 1.511; 95% CI 1.196, 1.908), driven by a higher likelihood of switching again (adjusted hazard ratio, 2.016; 95% CI 1.428, 2.847). Clinical outcomes were evaluable for 239 (53.3%) TNFi cyclers and 209 (46.7%) new MOA switchers. One-year mean reduction in CDAI from baseline to end of follow-up was significantly higher for new MOA switchers than TNFi cyclers (−7.54 vs. −4.81; P = 0.037), but the difference was not statistically significant after adjustment for baseline CDAI (−6.39 vs. −5.83; P = 0.607).ConclusionIn this study, TNFi cycling was common in clinical practice, but switching to a new MOA DMARD was associated with significantly better treatment persistence and a trend toward greater CDAI reduction that was not significant after adjustment for baseline disease activity.FundingSanofi and Regeneron Pharmaceuticals. More... »

PAGES

1936-1952

References to SciGraph publications

  • 2011-06-07. Outcomes of switching anti-TNF drugs in rheumatoid arthritis—a study based on observational data from the Finnish Register of Biological Treatment (ROB-FIN) in CLINICAL RHEUMATOLOGY
  • 2014-06-28. Clinical efficacy of abatacept, tocilizumab, and etanercept in Japanese rheumatoid arthritis patients with inadequate response to anti-TNF monoclonal antibodies in CLINICAL RHEUMATOLOGY
  • 2015-10-08. Non-adherence to disease-modifying antirheumatic drugs is associated with higher disease activity in early arthritis patients in the first year of the disease in ARTHRITIS RESEARCH & THERAPY
  • 2009-04-06. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review in ARTHRITIS RESEARCH & THERAPY
  • 2009-07-23. DAS-28-based EULAR response and HAQ improvement in rheumatoid arthritis patients switching between TNF antagonists in BMC MUSCULOSKELETAL DISORDERS
  • 2014-01-28. Comparative effectiveness of cycling of tumor necrosis factor-α (TNF-α) inhibitors versus switching to non-TNF biologics in rheumatoid arthritis patients with inadequate response to TNF-α inhibitor using a Bayesian approach in ARCHIVES OF PHARMACAL RESEARCH
  • 2005-04-07. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score in ARTHRITIS RESEARCH & THERAPY
  • 2014-09-23. Response to Biologic Disease-Modifying Anti-Rheumatic Drugs after Discontinuation of Anti-Tumor Necrosis Factor Alpha Agents for Rheumatoid Arthritis in RHEUMATOLOGY AND THERAPY
  • 2008-04. Rheumatoid Arthritis in DRUGS
  • 2015-09-07. Retention of the second-line biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis failing one tumor necrosis factor alpha inhibitor: data from the BioRx.si registry in CLINICAL RHEUMATOLOGY
  • 2009-02-19. Medication persistence over 2 years of follow-up in a cohort of early rheumatoid arthritis patients: associated factors and relationship with disease activity and with disability in ARTHRITIS RESEARCH & THERAPY
  • 2015-07-11. Window of opportunity to achieve major outcomes in early rheumatoid arthritis patients: how persistence with therapy matters in ARTHRITIS RESEARCH & THERAPY
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s12325-017-0578-8

    DOI

    http://dx.doi.org/10.1007/s12325-017-0578-8

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1090336745

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/28674959


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Clinical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antirheumatic Agents", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Arthritis, Rheumatoid", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Dose-Response Relationship, Drug", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Drug Substitution", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Female", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Longitudinal Studies", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Male", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Medication Adherence", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Middle Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Retrospective Studies", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Rituximab", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Treatment Outcome", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Tumor Necrosis Factor-alpha", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "United States", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA", 
              "id": "http://www.grid.ac/institutes/grid.418961.3", 
              "name": [
                "Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Wei", 
            "givenName": "Wenhui", 
            "id": "sg:person.01202153526.33", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01202153526.33"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Discus Analytics, LLC, Spokane, WA, USA", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Discus Analytics, LLC, Spokane, WA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Knapp", 
            "givenName": "Keith", 
            "id": "sg:person.015027270653.20", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015027270653.20"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "STATinMED Research, Plano, TX, USA", 
              "id": "http://www.grid.ac/institutes/grid.459967.0", 
              "name": [
                "STATinMED Research, Plano, TX, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Wang", 
            "givenName": "Li", 
            "id": "sg:person.01053215665.29", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01053215665.29"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA", 
              "id": "http://www.grid.ac/institutes/grid.418961.3", 
              "name": [
                "Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Chen", 
            "givenName": "Chieh-I", 
            "id": "sg:person.01063175300.20", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01063175300.20"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Discus Analytics, LLC, Spokane, WA, USA", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Discus Analytics, LLC, Spokane, WA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Craig", 
            "givenName": "Gary L.", 
            "id": "sg:person.07717160453.94", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07717160453.94"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Discus Analytics, LLC, Spokane, WA, USA", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Discus Analytics, LLC, Spokane, WA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Ferguson", 
            "givenName": "Karen", 
            "id": "sg:person.010514541053.39", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010514541053.39"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "The Hospital for Special Surgery, New York, NY, USA", 
              "id": "http://www.grid.ac/institutes/grid.239915.5", 
              "name": [
                "The Hospital for Special Surgery, New York, NY, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Schwartzman", 
            "givenName": "Sergio", 
            "id": "sg:person.014133305773.18", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014133305773.18"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.2165/00003495-200868050-00003", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1029580346", 
              "https://doi.org/10.2165/00003495-200868050-00003"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s13075-015-0801-4", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1021221813", 
              "https://doi.org/10.1186/s13075-015-0801-4"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s10067-011-1779-1", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1029448692", 
              "https://doi.org/10.1007/s10067-011-1779-1"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s12272-014-0337-1", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1033724339", 
              "https://doi.org/10.1007/s12272-014-0337-1"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/ar2620", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1049370456", 
              "https://doi.org/10.1186/ar2620"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s13075-015-0697-z", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1012494697", 
              "https://doi.org/10.1186/s13075-015-0697-z"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/ar2666", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1052341264", 
              "https://doi.org/10.1186/ar2666"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/ar1740", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1025234427", 
              "https://doi.org/10.1186/ar1740"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s10067-015-3066-z", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1032937497", 
              "https://doi.org/10.1007/s10067-015-3066-z"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/1471-2474-10-91", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1039263381", 
              "https://doi.org/10.1186/1471-2474-10-91"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s40744-014-0002-7", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1027027028", 
              "https://doi.org/10.1007/s40744-014-0002-7"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s10067-014-2711-2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1027778243", 
              "https://doi.org/10.1007/s10067-014-2711-2"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2017-07-03", 
        "datePublishedReg": "2017-07-03", 
        "description": "IntroductionTo examine treatment persistence and clinical outcomes associated with switching from a tumor necrosis factor inhibitor (TNFi) to a medication with a new mechanism of action (MOA) (abatacept, anakinra, rituximab, tocilizumab, or tofacitinib) versus cycling to another TNFi (adalimumab, certolizumab pegol, etanercept, golimumab, or infliximab) among patients with rheumatoid arthritis.MethodsThis retrospective, longitudinal study included patients with rheumatoid arthritis in the JointMan\u00ae US clinical database who received a TNFi in April 2010 or later and either cycled to a TNFi or switched to a new MOA therapy by March 2015. Cox proportional hazards models were used for time to non-persistence (switching or discontinuing). An ordinary least squares regression model compared 1-year reduction from baseline for the Clinical Disease Activity Index (CDAI).ResultsThere were 332 (54.2%) TNFi cyclers and 281 (45.8%) new MOA switchers. During a median follow-up of 29.9\u00a0months, treatment persistence was 36.7% overall. Compared with new MOA switchers, TNFi cyclers were 51% more likely to be non-persistent (adjusted hazard ratio, 1.511; 95% CI 1.196, 1.908), driven by a higher likelihood of switching again (adjusted hazard ratio, 2.016; 95% CI 1.428, 2.847). Clinical outcomes were evaluable for 239 (53.3%) TNFi cyclers and 209 (46.7%) new MOA switchers. One-year mean reduction in CDAI from baseline to end of follow-up was significantly higher for new MOA switchers than TNFi cyclers (\u22127.54 vs. \u22124.81; P\u00a0=\u00a00.037), but the difference was not statistically significant after adjustment for baseline CDAI (\u22126.39 vs. \u22125.83; P\u00a0=\u00a00.607).ConclusionIn this study, TNFi cycling was common in clinical practice, but switching to a new MOA DMARD was associated with significantly better treatment persistence and a trend toward greater CDAI reduction that was not significant after adjustment for baseline disease activity.FundingSanofi and Regeneron Pharmaceuticals.", 
        "genre": "article", 
        "id": "sg:pub.10.1007/s12325-017-0578-8", 
        "isAccessibleForFree": true, 
        "isPartOf": [
          {
            "id": "sg:journal.1096634", 
            "issn": [
              "0741-238X", 
              "1865-8652"
            ], 
            "name": "Advances in Therapy", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "8", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "34"
          }
        ], 
        "keywords": [
          "tumor necrosis factor inhibitors", 
          "Clinical Disease Activity Index", 
          "TNFi cyclers", 
          "treatment persistence", 
          "clinical outcomes", 
          "rheumatoid arthritis", 
          "prior tumour necrosis factor inhibitor therapy", 
          "baseline Clinical Disease Activity Index", 
          "tumor necrosis factor inhibitor therapy", 
          "necrosis factor inhibitor therapy", 
          "real-world observational study", 
          "better treatment persistence", 
          "disease activity index", 
          "baseline disease activity", 
          "necrosis factor inhibitors", 
          "rheumatoid arthritis patients", 
          "proportional hazards model", 
          "TNFi cycling", 
          "disease activity", 
          "inhibitor therapy", 
          "arthritis patients", 
          "factor inhibitors", 
          "Regeneron Pharmaceuticals", 
          "observational study", 
          "mean reduction", 
          "hazards model", 
          "clinical practice", 
          "clinical database", 
          "activity index", 
          "patients", 
          "therapy", 
          "higher likelihood", 
          "longitudinal study", 
          "arthritis", 
          "outcomes", 
          "action therapy", 
          "baseline", 
          "regression models", 
          "DMARDs", 
          "MethodsThis", 
          "medications", 
          "ResultsThere", 
          "IntroductionTo", 
          "ConclusionIn", 
          "new mechanism", 
          "months", 
          "persistence", 
          "study", 
          "adjustment", 
          "United States", 
          "cycler", 
          "reduction", 
          "inhibitors", 
          "ordinary least squares regression models", 
          "mechanism", 
          "index", 
          "switchers", 
          "differences", 
          "database", 
          "likelihood", 
          "activity", 
          "action", 
          "least squares regression models", 
          "squares regression models", 
          "practice", 
          "time", 
          "pharmaceuticals", 
          "model", 
          "trends", 
          "cycling", 
          "state"
        ], 
        "name": "Treatment Persistence and Clinical Outcomes of Tumor Necrosis Factor Inhibitor Cycling or Switching to a New Mechanism of Action Therapy: Real-world Observational Study of Rheumatoid Arthritis Patients in the United States with Prior Tumor Necrosis Factor Inhibitor Therapy", 
        "pagination": "1936-1952", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1090336745"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s12325-017-0578-8"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "28674959"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s12325-017-0578-8", 
          "https://app.dimensions.ai/details/publication/pub.1090336745"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-12-01T06:35", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_722.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1007/s12325-017-0578-8"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12325-017-0578-8'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12325-017-0578-8'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12325-017-0578-8'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12325-017-0578-8'


     

    This table displays all metadata directly associated to this object as RDF triples.

    291 TRIPLES      21 PREDICATES      123 URIs      103 LITERALS      22 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s12325-017-0578-8 schema:about N0e6295f6beb94e4b8557e71279fc26a3
    2 N283e5baef83941969ebd1bbcf5ce007a
    3 N3567a9475b224a9c887839571fcbf7e5
    4 N3a57a431f8694690b136ea258482dfc6
    5 N3cdccdf2a8dd49f496eb481ae35d7335
    6 N4c213dcff6ca4061b0f23d960335be21
    7 N603a23d0b5f1479d9338ebc86ec20e35
    8 N854b9020eae7496bb0583984e46a4840
    9 N9d956f14e9bb443881c9995469ee46a6
    10 Nbe812603e74c4bacb8379ef76f6c9368
    11 Nc18663f424b84014aea1d6bbbbcee05f
    12 Nc1cc157822e54dbd86e9514bbed64588
    13 Ne98e6ce40bd34c5ab2f640a516d227d7
    14 Nf6202660fd80451cada84ab08021a402
    15 Nfd1c2335f2a346808f769210d920bf6b
    16 anzsrc-for:11
    17 anzsrc-for:1103
    18 schema:author Nab2aacd7fc5d41958401b9d8836ef2ea
    19 schema:citation sg:pub.10.1007/s10067-011-1779-1
    20 sg:pub.10.1007/s10067-014-2711-2
    21 sg:pub.10.1007/s10067-015-3066-z
    22 sg:pub.10.1007/s12272-014-0337-1
    23 sg:pub.10.1007/s40744-014-0002-7
    24 sg:pub.10.1186/1471-2474-10-91
    25 sg:pub.10.1186/ar1740
    26 sg:pub.10.1186/ar2620
    27 sg:pub.10.1186/ar2666
    28 sg:pub.10.1186/s13075-015-0697-z
    29 sg:pub.10.1186/s13075-015-0801-4
    30 sg:pub.10.2165/00003495-200868050-00003
    31 schema:datePublished 2017-07-03
    32 schema:datePublishedReg 2017-07-03
    33 schema:description IntroductionTo examine treatment persistence and clinical outcomes associated with switching from a tumor necrosis factor inhibitor (TNFi) to a medication with a new mechanism of action (MOA) (abatacept, anakinra, rituximab, tocilizumab, or tofacitinib) versus cycling to another TNFi (adalimumab, certolizumab pegol, etanercept, golimumab, or infliximab) among patients with rheumatoid arthritis.MethodsThis retrospective, longitudinal study included patients with rheumatoid arthritis in the JointMan® US clinical database who received a TNFi in April 2010 or later and either cycled to a TNFi or switched to a new MOA therapy by March 2015. Cox proportional hazards models were used for time to non-persistence (switching or discontinuing). An ordinary least squares regression model compared 1-year reduction from baseline for the Clinical Disease Activity Index (CDAI).ResultsThere were 332 (54.2%) TNFi cyclers and 281 (45.8%) new MOA switchers. During a median follow-up of 29.9 months, treatment persistence was 36.7% overall. Compared with new MOA switchers, TNFi cyclers were 51% more likely to be non-persistent (adjusted hazard ratio, 1.511; 95% CI 1.196, 1.908), driven by a higher likelihood of switching again (adjusted hazard ratio, 2.016; 95% CI 1.428, 2.847). Clinical outcomes were evaluable for 239 (53.3%) TNFi cyclers and 209 (46.7%) new MOA switchers. One-year mean reduction in CDAI from baseline to end of follow-up was significantly higher for new MOA switchers than TNFi cyclers (−7.54 vs. −4.81; P = 0.037), but the difference was not statistically significant after adjustment for baseline CDAI (−6.39 vs. −5.83; P = 0.607).ConclusionIn this study, TNFi cycling was common in clinical practice, but switching to a new MOA DMARD was associated with significantly better treatment persistence and a trend toward greater CDAI reduction that was not significant after adjustment for baseline disease activity.FundingSanofi and Regeneron Pharmaceuticals.
    34 schema:genre article
    35 schema:isAccessibleForFree true
    36 schema:isPartOf N2e8eb4a3ffae4554a8b2e19aa145a347
    37 N7b20d6457d9d47a28555b8b7c0596902
    38 sg:journal.1096634
    39 schema:keywords Clinical Disease Activity Index
    40 ConclusionIn
    41 DMARDs
    42 IntroductionTo
    43 MethodsThis
    44 Regeneron Pharmaceuticals
    45 ResultsThere
    46 TNFi cyclers
    47 TNFi cycling
    48 United States
    49 action
    50 action therapy
    51 activity
    52 activity index
    53 adjustment
    54 arthritis
    55 arthritis patients
    56 baseline
    57 baseline Clinical Disease Activity Index
    58 baseline disease activity
    59 better treatment persistence
    60 clinical database
    61 clinical outcomes
    62 clinical practice
    63 cycler
    64 cycling
    65 database
    66 differences
    67 disease activity
    68 disease activity index
    69 factor inhibitors
    70 hazards model
    71 higher likelihood
    72 index
    73 inhibitor therapy
    74 inhibitors
    75 least squares regression models
    76 likelihood
    77 longitudinal study
    78 mean reduction
    79 mechanism
    80 medications
    81 model
    82 months
    83 necrosis factor inhibitor therapy
    84 necrosis factor inhibitors
    85 new mechanism
    86 observational study
    87 ordinary least squares regression models
    88 outcomes
    89 patients
    90 persistence
    91 pharmaceuticals
    92 practice
    93 prior tumour necrosis factor inhibitor therapy
    94 proportional hazards model
    95 real-world observational study
    96 reduction
    97 regression models
    98 rheumatoid arthritis
    99 rheumatoid arthritis patients
    100 squares regression models
    101 state
    102 study
    103 switchers
    104 therapy
    105 time
    106 treatment persistence
    107 trends
    108 tumor necrosis factor inhibitor therapy
    109 tumor necrosis factor inhibitors
    110 schema:name Treatment Persistence and Clinical Outcomes of Tumor Necrosis Factor Inhibitor Cycling or Switching to a New Mechanism of Action Therapy: Real-world Observational Study of Rheumatoid Arthritis Patients in the United States with Prior Tumor Necrosis Factor Inhibitor Therapy
    111 schema:pagination 1936-1952
    112 schema:productId N7a06eac5fddf421098a78b82d9370270
    113 Nbb3ccc466514441d8d01a98f51fb200a
    114 Nbcbbc1876fbd42c1bf9c415d13c670dd
    115 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090336745
    116 https://doi.org/10.1007/s12325-017-0578-8
    117 schema:sdDatePublished 2022-12-01T06:35
    118 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    119 schema:sdPublisher Na240bc58bc194403914532e2a4c58f7a
    120 schema:url https://doi.org/10.1007/s12325-017-0578-8
    121 sgo:license sg:explorer/license/
    122 sgo:sdDataset articles
    123 rdf:type schema:ScholarlyArticle
    124 N0e6295f6beb94e4b8557e71279fc26a3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    125 schema:name Male
    126 rdf:type schema:DefinedTerm
    127 N283e5baef83941969ebd1bbcf5ce007a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    128 schema:name Dose-Response Relationship, Drug
    129 rdf:type schema:DefinedTerm
    130 N2e8eb4a3ffae4554a8b2e19aa145a347 schema:issueNumber 8
    131 rdf:type schema:PublicationIssue
    132 N3567a9475b224a9c887839571fcbf7e5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    133 schema:name Rituximab
    134 rdf:type schema:DefinedTerm
    135 N3a57a431f8694690b136ea258482dfc6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    136 schema:name Arthritis, Rheumatoid
    137 rdf:type schema:DefinedTerm
    138 N3cdccdf2a8dd49f496eb481ae35d7335 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    139 schema:name Female
    140 rdf:type schema:DefinedTerm
    141 N45ae1bbcb32240c6ba7e695510a2738f rdf:first sg:person.010514541053.39
    142 rdf:rest Nfccbf379b5ae453e83c761825aece0f5
    143 N4c213dcff6ca4061b0f23d960335be21 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    144 schema:name Treatment Outcome
    145 rdf:type schema:DefinedTerm
    146 N5cfa7b239e6f4584bd6661a8774ca31a rdf:first sg:person.07717160453.94
    147 rdf:rest N45ae1bbcb32240c6ba7e695510a2738f
    148 N603a23d0b5f1479d9338ebc86ec20e35 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    149 schema:name United States
    150 rdf:type schema:DefinedTerm
    151 N7a06eac5fddf421098a78b82d9370270 schema:name dimensions_id
    152 schema:value pub.1090336745
    153 rdf:type schema:PropertyValue
    154 N7b20d6457d9d47a28555b8b7c0596902 schema:volumeNumber 34
    155 rdf:type schema:PublicationVolume
    156 N854b9020eae7496bb0583984e46a4840 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    157 schema:name Retrospective Studies
    158 rdf:type schema:DefinedTerm
    159 N9d956f14e9bb443881c9995469ee46a6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    160 schema:name Middle Aged
    161 rdf:type schema:DefinedTerm
    162 Na240bc58bc194403914532e2a4c58f7a schema:name Springer Nature - SN SciGraph project
    163 rdf:type schema:Organization
    164 Nab2aacd7fc5d41958401b9d8836ef2ea rdf:first sg:person.01202153526.33
    165 rdf:rest Nbe0b8fb4793b4a7d9b047e31edff8199
    166 Nbb3ccc466514441d8d01a98f51fb200a schema:name doi
    167 schema:value 10.1007/s12325-017-0578-8
    168 rdf:type schema:PropertyValue
    169 Nbcbbc1876fbd42c1bf9c415d13c670dd schema:name pubmed_id
    170 schema:value 28674959
    171 rdf:type schema:PropertyValue
    172 Nbe0b8fb4793b4a7d9b047e31edff8199 rdf:first sg:person.015027270653.20
    173 rdf:rest Nef192fdc6de24edfb3c1fba55783d668
    174 Nbe812603e74c4bacb8379ef76f6c9368 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    175 schema:name Medication Adherence
    176 rdf:type schema:DefinedTerm
    177 Nc18663f424b84014aea1d6bbbbcee05f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    178 schema:name Longitudinal Studies
    179 rdf:type schema:DefinedTerm
    180 Nc1cc157822e54dbd86e9514bbed64588 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    181 schema:name Drug Substitution
    182 rdf:type schema:DefinedTerm
    183 Ne98e6ce40bd34c5ab2f640a516d227d7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    184 schema:name Humans
    185 rdf:type schema:DefinedTerm
    186 Ne9eb9b4bb5ce4cdcaa12196ffe138d72 rdf:first sg:person.01063175300.20
    187 rdf:rest N5cfa7b239e6f4584bd6661a8774ca31a
    188 Nef192fdc6de24edfb3c1fba55783d668 rdf:first sg:person.01053215665.29
    189 rdf:rest Ne9eb9b4bb5ce4cdcaa12196ffe138d72
    190 Nf6202660fd80451cada84ab08021a402 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    191 schema:name Antirheumatic Agents
    192 rdf:type schema:DefinedTerm
    193 Nfccbf379b5ae453e83c761825aece0f5 rdf:first sg:person.014133305773.18
    194 rdf:rest rdf:nil
    195 Nfd1c2335f2a346808f769210d920bf6b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    196 schema:name Tumor Necrosis Factor-alpha
    197 rdf:type schema:DefinedTerm
    198 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    199 schema:name Medical and Health Sciences
    200 rdf:type schema:DefinedTerm
    201 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
    202 schema:name Clinical Sciences
    203 rdf:type schema:DefinedTerm
    204 sg:journal.1096634 schema:issn 0741-238X
    205 1865-8652
    206 schema:name Advances in Therapy
    207 schema:publisher Springer Nature
    208 rdf:type schema:Periodical
    209 sg:person.010514541053.39 schema:affiliation grid-institutes:None
    210 schema:familyName Ferguson
    211 schema:givenName Karen
    212 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010514541053.39
    213 rdf:type schema:Person
    214 sg:person.01053215665.29 schema:affiliation grid-institutes:grid.459967.0
    215 schema:familyName Wang
    216 schema:givenName Li
    217 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01053215665.29
    218 rdf:type schema:Person
    219 sg:person.01063175300.20 schema:affiliation grid-institutes:grid.418961.3
    220 schema:familyName Chen
    221 schema:givenName Chieh-I
    222 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01063175300.20
    223 rdf:type schema:Person
    224 sg:person.01202153526.33 schema:affiliation grid-institutes:grid.418961.3
    225 schema:familyName Wei
    226 schema:givenName Wenhui
    227 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01202153526.33
    228 rdf:type schema:Person
    229 sg:person.014133305773.18 schema:affiliation grid-institutes:grid.239915.5
    230 schema:familyName Schwartzman
    231 schema:givenName Sergio
    232 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014133305773.18
    233 rdf:type schema:Person
    234 sg:person.015027270653.20 schema:affiliation grid-institutes:None
    235 schema:familyName Knapp
    236 schema:givenName Keith
    237 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015027270653.20
    238 rdf:type schema:Person
    239 sg:person.07717160453.94 schema:affiliation grid-institutes:None
    240 schema:familyName Craig
    241 schema:givenName Gary L.
    242 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07717160453.94
    243 rdf:type schema:Person
    244 sg:pub.10.1007/s10067-011-1779-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029448692
    245 https://doi.org/10.1007/s10067-011-1779-1
    246 rdf:type schema:CreativeWork
    247 sg:pub.10.1007/s10067-014-2711-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027778243
    248 https://doi.org/10.1007/s10067-014-2711-2
    249 rdf:type schema:CreativeWork
    250 sg:pub.10.1007/s10067-015-3066-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1032937497
    251 https://doi.org/10.1007/s10067-015-3066-z
    252 rdf:type schema:CreativeWork
    253 sg:pub.10.1007/s12272-014-0337-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033724339
    254 https://doi.org/10.1007/s12272-014-0337-1
    255 rdf:type schema:CreativeWork
    256 sg:pub.10.1007/s40744-014-0002-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027027028
    257 https://doi.org/10.1007/s40744-014-0002-7
    258 rdf:type schema:CreativeWork
    259 sg:pub.10.1186/1471-2474-10-91 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039263381
    260 https://doi.org/10.1186/1471-2474-10-91
    261 rdf:type schema:CreativeWork
    262 sg:pub.10.1186/ar1740 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025234427
    263 https://doi.org/10.1186/ar1740
    264 rdf:type schema:CreativeWork
    265 sg:pub.10.1186/ar2620 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049370456
    266 https://doi.org/10.1186/ar2620
    267 rdf:type schema:CreativeWork
    268 sg:pub.10.1186/ar2666 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052341264
    269 https://doi.org/10.1186/ar2666
    270 rdf:type schema:CreativeWork
    271 sg:pub.10.1186/s13075-015-0697-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1012494697
    272 https://doi.org/10.1186/s13075-015-0697-z
    273 rdf:type schema:CreativeWork
    274 sg:pub.10.1186/s13075-015-0801-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021221813
    275 https://doi.org/10.1186/s13075-015-0801-4
    276 rdf:type schema:CreativeWork
    277 sg:pub.10.2165/00003495-200868050-00003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029580346
    278 https://doi.org/10.2165/00003495-200868050-00003
    279 rdf:type schema:CreativeWork
    280 grid-institutes:None schema:alternateName Discus Analytics, LLC, Spokane, WA, USA
    281 schema:name Discus Analytics, LLC, Spokane, WA, USA
    282 rdf:type schema:Organization
    283 grid-institutes:grid.239915.5 schema:alternateName The Hospital for Special Surgery, New York, NY, USA
    284 schema:name The Hospital for Special Surgery, New York, NY, USA
    285 rdf:type schema:Organization
    286 grid-institutes:grid.418961.3 schema:alternateName Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
    287 schema:name Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
    288 rdf:type schema:Organization
    289 grid-institutes:grid.459967.0 schema:alternateName STATinMED Research, Plano, TX, USA
    290 schema:name STATinMED Research, Plano, TX, USA
    291 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...